RWA Wealth Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$406K Hold
2,563
﹤0.01% 508
2026
Q1
$327K Hold
2,563
﹤0.01% 523
2025
Q4
$313K Sell
2,563
-46
-2% -$5.27K ﹤0.01% 515
2025
Q3
$261K Hold
2,609
﹤0.01% 550
2025
Q2
$216K Sell
2,609
-929
-26% -$74.1K ﹤0.01% 564
2025
Q1
$287K Sell
3,538
-15
-0.4% -$1.34K ﹤0.01% 488
2024
Q4
$320K Buy
3,553
+1,508
+74% +$146K ﹤0.01% 478
2024
Q3
$202K Buy
+2,045
New +$201K ﹤0.01% 545
2018
Q3
Sell
-300
Closed -$29K 705
2018
Q2
$29K Buy
+300
New +$27.6K ﹤0.01% 490

Other funds holding XBI

RWA Wealth Partners's XBI Position: Q2 2026 in Review

RWA Wealth Partners held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 2,563 shares worth $406K. The position accounts for ﹤0.01% of the portfolio, ranked #508.

RWA Wealth Partners first reported a position in XBI in Q2 2018 and has held it in 9 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • RWA Wealth Partners held 2,563 shares of State Street SPDR S&P Biotech ETF worth $406K as of Q2 2026.
  • RWA Wealth Partners left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of RWA Wealth Partners's portfolio in Q2 2026, its #508 holding.
  • RWA Wealth Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and has held it in 9 quarters since.
  • 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on RWA Wealth Partners's 13F filing for Q2 2026, filed 7 Aug 2026.